This is a useful secondary analysis of the REACH trial, determining whether serum infliximab concentration is associated with improved outcomes among pediatric patients with moderate-to-severe Crohn’s disease. My only concern is whether serum infliximab concentrations were collected at weeks 2, 6 and 10, as needed by the investigators. This should be confirmed with the clinical trial team at Janssen.
Recommendation for this data request: Approve